Pacira BioSciences' Short term Debt was N/A to $202.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $202.4 million, marking a year-over-year change of. This contributed to the annual value of $201.8 million for FY2024, which is 2235.10% up from last year.
Latest data reveals that Pacira BioSciences reported Short term Debt of $202.4 million as of Q2 2025, which was up 0.15% from $202.1 million recorded in Q1 2025.
Pacira BioSciences' 5-year Short term Debt high stood at $350.5 million for Q4 2021, and its period low was $8.6 million during Q3 2023.
For the 3-year period, Pacira BioSciences' Short term Debt averaged around $95.0 million, with its median value being $10.9 million (2023).
In the last 5 years, Pacira BioSciences' Short term Debt crashed by 93.22% in 2023 and then skyrocketed by 2,238.69% in 2025.
Quarterly analysis of 5 years shows Pacira BioSciences' Short term Debt stood at $350.5 million in 2021, then plummeted by 90.40% to $33.6 million in 2022, then crashed by 74.32% to $8.6 million in 2023, then soared by 2,235.10% to $201.8 million in 2024, then soared by 2,238.69% to $202.4 million in 2025.
Its Short term Debt was $202.4 million in Q2 2025, compared to $202.1 million in Q1 2025 and $201.8 million in Q4 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value